Today we announced that results from the MOTION pivotal Phase 3 study of vimseltinib are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, and have been published in The Lancet. Read the press release here: https://lnkd.in/ed7TGdyc
Deciphera Pharmaceuticals
Pharmaceutical Manufacturing
Waltham, Massachusetts 39,916 followers
About us
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. For more information, visit www.deciphera.com.
- Website
-
http://www.deciphera.com
External link for Deciphera Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Public Company
- Founded
- 2003
Locations
Employees at Deciphera Pharmaceuticals
Updates
-
Last week on May 21st, World Day for Cultural Diversity, we came together for a virtual social hour to connect and celebrate the richness that our unique cultural backgrounds bring to our work at Deciphera. Our incredible team comprises individuals from diverse backgrounds and talents, all united by our passion to improve the lives of people living with cancer. Diversity and Inclusion are integral to innovation and progress at Deciphera, and we are committed to fostering an inclusive workplace for all. #GreatPlaceToWork #TheDecipheraDifference
-
This Memorial Day, we remember and honor those who made the ultimate sacrifice for our nation. Their courage and dedication will not be forgotten. #MemorialDay
-
We are excited to announce that Deciphera has entered into an agreement to be acquired by ONO Pharmaceutical for $2.4 billion. Together, we will accelerate our shared vision to deliver innovative new drugs and serve patients around the world. Deciphera’s specialized capabilities in kinase drug discovery, our well-established commercial and sales platforms throughout the United States and Europe, and global clinical development capabilities will enable ONO to build a robust presence in oncology. As part of ONO, we will be positioned to advance our work to bring QINLOCK and potentially vimseltinib to more people, sooner than we could as an independent company. For more details, please view the news release and other important information here: https://lnkd.in/gE69XdJ9
-
Deciphera is participating in a fireside chat at the Stifel Financial Corp. 2024 Virtual Targeted Oncology Forum today at 11:30 AM ET. View the webcast here: https://lnkd.in/dYZ59Js
-
Deciphera is presenting preclinical data for DCC-3084 at the American Association for Cancer Research (AACR) Annual Meeting 2024, on Sunday, April 7 in San Diego, CA. #AACR24
-
We are pleased to present on the discovery of DCC-3116 at the American Chemical Society (ACS) Spring Meeting 2024 in New Orleans today. Learn more: https://bit.ly/3TrUMOe #ACSSpring2024
-
On International Women’s Day, and every day, we celebrate the remarkable achievements of the women at Deciphera, across the industry and worldwide. Thanks to Jama Jameson Pitman, our Chief Development Officer, for her reflections. #IWD2024 #InspireInclusion
-
Deciphera Pharmaceuticals reposted this
This #RareDiseaseDay and year-round, we recognize that tremendous progress has been made in the fight against #cancer but there is still so much more work to be done, especially for people living with rare diseases like #GIST and #TGCT. Learn more about the Deciphera difference: https://lnkd.in/eBcBEYhM
-
This #RareDiseaseDay and year-round, we recognize that tremendous progress has been made in the fight against #cancer but there is still so much more work to be done, especially for people living with rare diseases like #GIST and #TGCT. Learn more about the Deciphera difference: https://lnkd.in/eBcBEYhM